HNO223 Cells
| Unit |
3 x 10^6 cells/ml |
|---|---|
| Cell Type |
Tumor Cells |
| Tissue Type |
Head-Neck cancer cell lines |
| Organism |
Human |
| Donor History |
Head and neck squamous cell carcinoma (HNSCC) |
| Growth Properties |
Monolayer ,adherent |
| Growth Conditions |
Culture medium: DMEM ,w: 4.5 g/L Glucose ,w: 4 mM L-Glutamine ,w: 3.7 g/L NaHCO3 ,w: 1.0 mM Sodium pyruvate (Cytion article number 820300a). Supplements: Supplement the medium with 10% FBS. Dissociation reagent: Accutase. Freeze medium: As a cryopreservation medium ,we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability ,or CM-1 (Cytion catalog number 800100) ,which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Incubation atmosphere: 37°C ,5% CO2 ,humidified atmosphere. |
| Immortalization Method | |
| Full Information |
The HNO223 cell line is derived from an oral squamous cell carcinoma, which is a subtype of head and neck squamous cell carcinoma (HNSCC). This cell line has been cytogenetically characterized, revealing significant DNA copy number gains in several chromosomal regions, including 3q22-qter, 8q, 9p, 9q, 11q13, 20p, and 20q. These regions are of particular interest as they frequently contain oncogenes implicated in the progression of HNSCC, such as those involved in cell proliferation, survival, and metastasis. The amplification of 11q13, observed in HNO223, is associated with the overexpression of key oncogenes like CCND1 (cyclin D1) and CTTN (cortactin), which are known to contribute to the aggressive behavior of cancer cells, including enhanced cell cycle progression and increased invasiveness. This makes HNO223 a relevant model for investigating the molecular pathways involved in oral squamous cell carcinoma and for exploring therapeutic strategies targeting these genetic alterations. HNO223 serves as a robust model in cancer research, particularly for studies aiming to understand the genetic and molecular underpinnings of HNSCC and for the development of targeted therapies that address these specific chromosomal abnormalities. Its genetic characteristics make it a valuable tool for both basic and translational research in oncology.
Společnost Cytion vznikla v roce 2004 v německém Heidelbergu s jasným vědeckým posláním: dodávat ověřené lidské a zvířecí buněčné linie bez kontaminace, připravené za přísně kontrolovaných laboratorních podmínek.
Postupně se vypracovala ve spolehlivou buněčnou banku, která slouží akademickým laboratořím, biotechnologickým firmám i farmaceutickým výzkumným týmům po celém světě. Klade přitom důraz na reprodukovatelnost výsledků, přísnou kontrolu kvality a dlouhodobá partnerství.
Mikrobiologické aplikace
NGS
Rapid testy
PCR plasty
Třepačky
Suché lázně
Fluorometry
Buněčné kultury
PCR, qPCR, RT
Detekce Mycoplasmat
Reverzní transkripce
Alergie
Intolerance
Elisa
Imunologické analyzátory
Veterinární imunologie
Alergie u zvířat
Intolerance u zvířat
Čtečky identifikačních čipů
Termočipy
Biochemie
Imunoanalýza

